| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2938889 | JACC: Cardiovascular Imaging | 2010 | 9 Pages |
Abstract
Cardiac sympathetic imaging with meta-iodobenzylguanidine (mIBG) is a noninvasive tool to risk stratify patients with heart failure (HF). In patients with ischemic and nonischemic cardiomyopathy, cardiac mIBG activity is a very powerful predictor of survival. Cardiac sympathetic imaging can help in understanding how sympathetic overactivity exerts its deleterious actions, which may result in better therapy and outcome for patients with HF.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ignasi Carrió, Martin R. Cowie, Junichi Yamazaki, James Udelson, Paolo G. Camici,